MOONLAKE IMMUNOTHERAPEUTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.75 USD | -2.72% |
|
-2.86% | -34.18% |
| 05-07 | MoonLake Immunotherapeutics Q1 Net Loss Widens | MT |
| 05-07 | MoonLake Immunotherapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 409.3 | 3,620 | 2,499 | - | - |
| Enterprise Value (EV) 1 | 337.2 | 3,109 | 2,037 | 2,127 | 2,187 |
| P/E ratio | -6.18 x | -82.7 x | -32.3 x | -22.5 x | -16.7 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | -6.09 x | -57.5 x | -22.1 x | -15.5 x | -11.7 x |
| EV / FCF | -6.03 x | -72.2 x | -22.4 x | -16.1 x | -8.08 x |
| FCF Yield | -16.6% | -1.39% | -4.46% | -6.21% | -12.4% |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 38,978 | 59,941 | 62,875 | - | - |
| Reference price 2 | 10.50 | 60.39 | 39.75 | 39.75 | 39.75 |
| Announcement Date | 20/03/23 | 29/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA 1 | -55.39 | -54.11 | -92.34 | -137.6 | -186.4 |
| EBIT 1 | -65.06 | -54.12 | -99.93 | -133.4 | -190.8 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -64.47 | -43.98 | -90.59 | -129.6 | -186.9 |
| Net income 1 | -49.97 | -36.01 | -84.2 | -106.7 | -156.9 |
| Net margin | - | - | - | - | - |
| EPS 2 | -1.700 | -0.7300 | -1.230 | -1.770 | -2.386 |
| Free Cash Flow 1 | -55.91 | -43.06 | -90.9 | -132 | -270.8 |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 20/03/23 | 29/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | - | - | - | - | - | - | - | -15.03 | -19.8 | -23.76 | -28.32 | -31.85 | - | - |
| EBIT 1 | - | -17.65 | -14.77 | -16.7 | -12.93 | -13.19 | -12.98 | -15.03 | -19.82 | -22.84 | -26.49 | -30.98 | -33.42 | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -17.41 | -14.73 | -16.46 | -12.21 | -12.34 | -11.59 | -7.843 | -13.91 | -20.56 | -25.34 | -30.79 | - | - |
| Net income 1 | -2.704 | -17.42 | -10.11 | -17.11 | -9.005 | -10.14 | -11.62 | -7.437 | -13.67 | -19.35 | -24.35 | -29.23 | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | - | -0.3400 | -0.2700 | -0.4300 | -0.2300 | -0.2300 | -0.1800 | -0.1200 | -0.2200 | -0.2919 | -0.3512 | -0.4108 | -0.7100 | -0.7800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 16/05/22 | 12/08/22 | 14/11/22 | 20/03/23 | 11/05/23 | 10/08/23 | 14/11/23 | 29/02/24 | 07/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | 72.1 | 511 | 462 | 372 | 312 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | -55.9 | -43.1 | -90.9 | -132 | -271 |
| ROE (net income / shareholders' equity) | - | -7.01% | -16.6% | -32.7% | -70.5% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | 0.02 | 0.28 | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 20/03/23 | 29/02/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
39.75
USD
Average target price
73.31
USD
Spread / Average Target
+84.42%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -34.18% | 2.5B | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -14.15% | 21.84B | |
| -1.05% | 21.96B | |
| -5.29% | 19.21B | |
| -38.29% | 17.71B | |
| -4.16% | 18.08B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- MLTX Stock
- Financials MoonLake Immunotherapeutics
